ArticleThe EMBO journal1998
D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain.
Article in The EMBO journal, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 90 citations in OpenAlex.
- Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.Expert review of anticancer therapy · 2019Review
- MYB - A regulatory factor in hematopoiesis.Gene · 2018Review
- Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.Cancer investigation · 2018Article
- ST2 gene products critically contribute to cellular transformation caused by an oncogenic Ras mutant.Heliyon · 2017Article
- miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb.Cell reports · 2017Article
- MicroRNA-548c-3p inhibits T98G glioma cell proliferation and migration by downregulating c-Myb.Oncology letters · 2017Article
- A photoactivatable Cre-loxP recombination system for optogenetic genome engineering.Nature chemical biology · 2016Article
- Cell cycle regulation of hematopoietic stem or progenitor cells.International journal of hematology · 2016Review
- Aberrant expression of cyclin D1 in cancer.Signal transduction insights · 2015Article
- Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis.Cancers · 2014Review
- Article
- Myb proteins: angels and demons in normal and transformed cells.Frontiers in bioscience (Landmark edition) · 2011Review
- Zinc finger transcription factor INSM1 interrupts cyclin D1 and CDK4 binding and induces cell cycle arrest.The Journal of biological chemistry · 2009Article
- Article
- A conserved acidic patch in the Myb domain is required for activation of an endogenous target gene and for chromatin binding.Molecular cancer · 2008Article
- Identification of an INSM1-binding site in the insulin promoter: negative regulation of the insulin gene transcription.The Journal of endocrinology · 2008Article
- Article
- Signal transduction involving the dmp1 transcription factor and its alteration in human cancer.Clinical medicine. Oncology · 2008Article
- Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition.Molecular and cellular biology · 2007Article
- Dmp1 and tumor suppression.Oncogene · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The v-Myb DNA-binding domain differs from that of c-Myb mainly by deletion of the first of three repeats. This truncation correlates with efficient oncogenic transformation and a decrease in DNA-binding activity. Here we demonstrate that the D-type cyclins, cyclin D1 and D2 in particular, specifically inhibit transcription when activated through the v-Myb DNA-binding domain, but not the c-Myb DNA-binding domain. Analysis of a cyclin D1 mutant and a dominant-negative CDK4 mutant implied that this repression is independent of complex formation with a CDK partner. Association of cyclin D1 and D2 with the Myb DNA-binding domain could be demonstrated. Increased levels of cyclin D1 and D2 resulted in a stabilization of the Myb proteins, but not in an alteration in binding of the Myb proteins to DNA. These results highlight an unexpected role for cyclin D as a CDK-independent repressor of transcriptional activation by v-Myb but not c-Myb. This differential effect of D-type cyclins on v-Myb and c-Myb might help to explain the mechanism underlying the oncogenic activity of v-Myb, which appears to be a stronger transcriptional activator following the TPA-induced differentiation of transformed monoblasts when cyclin D1 and D2 are down-regulated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.